Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma<sup>△</sup>

Shou* Li-hong; Cao Dan; Dong Xiao-hui; Fang Qiu; Xu Bao-lian; Fei Ju-ping

Your Location：

Home >

Browse articles >

Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma^△

中国医学科学杂志（英文版） 2016年31卷第3期页码：155-160

Orginal Article | Updated：2024-04-10

- Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma^△
- Affiliations：
  
  Department of Hematology, Huzhou Central Hospital, Huzhou,Zhejiang 313003, China
- Author bio：
- Funds：
- DOI：
  中图分类号：
- 网络出版日期：2016-06-20，
  
  纸质出版日期：2016-06
- Accepted：
Scan QR Code
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma^△[J]. 中国医学科学杂志（英文版）, 2016,31(3):155-160.

Shou* Li-hong, Cao Dan, Dong Xiao-hui, et al. Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma^△[J]. Chinese medical sciences journal, 2016, 31(3): 155-160.
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma^△[J]. 中国医学科学杂志（英文版）, 2016,31(3):155-160. DOI：

Shou* Li-hong, Cao Dan, Dong Xiao-hui, et al. Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma^△[J]. Chinese medical sciences journal, 2016, 31(3): 155-160. DOI：

摘要

Abstract

Objective

To determine the mRNA and protein levels of urokinase plasminogen activator receptors (uPAR) in bone marrow fluid and bone marrow tissue from multiple myeloma (MM) patients and assess association of uPAR level with prognosis of MM.

Methods

uPAR levels in bone marrow fluid of 22 MM patients at the stable and progressive stages and 18 iron deficiency anemia patients with normal bone marrow (control) were examined by ELISA. Furthermore

uPAR expression in bone marrow tissue was investigated by RT-PCR and Western blot

respectively. The distribution of uPAR in MM cells was examined using immunofluorescence staining. The pathological changes in different stages of MM patients were studied by HE staining.

Results

uPAR level in bone marrow fluid of MM patients (1.52±0.32 μg/ml) was found to be higher than that in the control group (0.98±0.15 μg/ml). Interestingly

uPAR protein (0.686±0.075

. 0.372±0.043

0.05) and mRNA (2.51±0.46

. 4.46±1.15

0.05) expression levels of MM patients at the progressive stage were significantly higher than those at the stable stage. The expression of uPAR in MM bone marrow was confirmed by immunofluorescence staining. Moreover

HE staining revealed a great increased number of nucleated cells and severe impairment of hematopoietic function in the bone marrow of patients with progressive-stage myeloma.

Conclusion

Our study reveals that uPAR expression is positively correlated with the development and progress of MM.

关键词

Keywords

references

Maiso P , Huynh D , Moschetta M , et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res 2015 ; 75 : 2071 - 82 .

Röllig C , Knop S , Bornhäuser M. Multiple myeloma. Lancet 2015 ; 385 : 2197 - 208 .

Mehta GR , Suhail F , Haddad RY. Multiple myeloma. Dis Mon 2014 ; 60 : 483 - 8 .

Qu YJ , Liu TW. The progress of multiple myeloma treat- ment. J Pract Oncol 2013 ; 4 : 351 - 5 .

Dass K , Ahmad A , Azmi AS , et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008 ; 34 : 122 - 36 .

Jacobsen B , Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008 ; 15 : 2559 - 73 .

Duffy MJ , O’Grady P , Devaney D , et al . Urokinase- plasminogen activator, a marker for aggressive breast carcinomas preliminary report. Cancer 1988 ; 18 : 531 - 6 .

Vassalli JD , Baccino D , Belin D. A cellular binding site for the Mr 55 000 form of the human plasminogen activator, urokinase. J Cell Biol 1985 ; 100 : 86 - 92 .

Béné MC , Castoldi G , Knapp W , et al. CD87 (urokinase- type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia 2004 ; 18 : 394 - 400 .

Luo LH , Xu GB , Lu XG. Detection and clinical significance of plasma urokinase-type lasminogen activator and its soluble receptor in patients with multiple myeloma. Zhejiang Da Xue Xue Bao Yi Xue Ban 2003 ; 32 : 529 - 32 .

Roodman GD. Role of the bone marrow microen- vironment in multiple myeloma. J Bone Miner Res 2002 ; 17 : 1921 - 5 .

Zhang ZN , Shen T. Standard diagnosis and curative effect of hematologic disease. 2nd ed. Beijing : Science Press , 1998 .

Bataille R , Jourdan M , Zhang XG , et al. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989 ; 84 : 2008 - 11 .

Smith HW , Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010 ; 11 : 23 - 36 .

Ferraris GM , Sidenius N. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteoly- sis, cell adhesion, and signal transduction. Semin Thromb Hemost 2013 ; 39 : 347 - 55 .

Magnussen S , Hadler-Olsen E , Latysheva N. Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes. PLoS One 2014 ; 9 : e105929 .

Zhuang T , Chelluboina B , Ponnala S , et al. Involvement of nitric oxide synthase in matrix metalloproteinase-9 and/ or urokinase plasminogen activator receptor-mediated glioma cell migration. BMC Cancer 2013 ; 13 : 590 .

Almasi CE , Drivsholm L , Pappot H , et al. The liberated domain I of urokinase plasminogen activator receptor—a new tumour marker in small cell lung cancer. APMIS 2013 ; 121 : 189 - 96 .

Ahn SB , Chan C , Dent OF , et al. Epithelial and stromal cell urokinase plasminogen activator receptor expression diff- erentially correlates with survival in rectal cancer stages B and C patients. PLoS One 2015 ; 10 : e0117786 .

Li Y , Sun B , Zhao X , et al. Subpopulations of uPAR (+) contribute to vasculogenic mimicry and metastasis in large cell lung cancer. Exp Mol Pathol 2015 ; 98 : 136 - 44 .

Dohn LH , Illemann M , Høyer-Hansen G , et al. Urokinase- type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial car-cinoma of the bladder . Urol Oncol 2015 ; 33: 165.e15 - 24 .

Magnussen S , Rikardsen OG , Hadler-Olsen E , et al. Urokinase plasminogen activator receptor (uPAR) and plasminogenactivator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). PLoS One 2014 ; 9 : e101895 .

Hou J , Li X , Li C , et al. Plasma membrane gp96 enhances invasion and metastatic potential of liver cancer via regulation of uPAR. Mol Oncol 2015 ; 9 : 1312 - 23 .

Laurenzana A , Biagioni A , Bianchini F , et al. Inhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells. J Mol Med 2015 ; 93 : 783 - 94 .

Hjertner O , Qvigstad G , Hjorth-Hansen H , et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 2000 ; 109 : 815 - 22 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

METHYLATION OF p16 AND p15 GENES IN MULTIPLE MYELOMA

PROCOAGULANT EFFECTS OF THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION

PREVENTION OF PERICARDIAL CONSTRICTION BY TRANSCATHETER INTRAPERICARDIAL FIBRINOLYSIS WITH UROKINASE

Multiple Myeloma Mimicking Spondyloarthritis: a Case Report